

Matthias Schwab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7173472/publications.pdf>

Version: 2024-02-01

211
papers

19,174
citations

14655

66
h-index

18130

120
g-index

222
all docs

222
docs citations

222
times ranked

21910
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, 138, 103-141. | | 2,924 |
| 2 | Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 169-174. | 4.7 | 628 |
| 3 | Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 399-415. | 5.7 | 556 |
| 4 | Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 392, 1093-1108. | 3.7 | 510 |
| 5 | Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on <i>TPMT</i> and <i>NUDT15</i> Genotypes: 2018 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1095-1105. | 4.7 | 428 |
| 6 | Sex is a major determinant of CYP3A4 expression in human liver. <i>Hepatology</i> , 2003, 38, 978-988. | 7.3 | 426 |
| 7 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 210-216. | 4.7 | 407 |
| 8 | Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel <i>TPMT</i> variants. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 407-417. | 5.7 | 393 |
| 9 | High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, <i>SLCO1B1</i>). <i>Pharmacogenetics and Genomics</i> , 2004, 14, 429-440. | 5.7 | 391 |
| 10 | <i>NUDT15</i> polymorphisms alter thiopurine metabolism and hematopoietic toxicity. <i>Nature Genetics</i> , 2016, 48, 367-373. | 21.4 | 389 |
| 11 | Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. <i>Journal of Hepatology</i> , 2016, 65, 490-498. | 3.7 | 321 |
| 12 | Expression of organic cation transporters OCT1 (<i>SLC22A1</i>) and OCT3 (<i>SLC22A3</i>) is affected by genetic factors and cholestasis in human liver. <i>Hepatology</i> , 2009, 50, 1227-1240. | 7.3 | 316 |
| 13 | Organic Cation Transporters (OCTs, MATEs), In Vitro and In Vivo Evidence for the Importance in Drug Therapy. <i>Handbook of Experimental Pharmacology</i> , 2011, , 105-167. | 1.8 | 312 |
| 14 | GENETIC POLYMORPHISMS OF THE HUMAN MDR1 DRUG TRANSPORTER. <i>Annual Review of Pharmacology and Toxicology</i> , 2003, 43, 285-307. | 9.4 | 294 |
| 15 | From hype to reality: data science enabling personalized medicine. <i>BMC Medicine</i> , 2018, 16, 150. | 5.5 | 278 |
| 16 | Clinical relevance of <i>DPYD</i> variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2015, 16, 1639-1650. | 10.7 | 277 |
| 17 | Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101. | 2.8 | 262 |
| 18 | Frequency of C3435T polymorphism of <i>MDR1</i> gene in African people. <i>Lancet</i> , The, 2001, 358, 383-384. | 13.7 | 260 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Thiopurine Methyltransferase (<EMPH TYPE="ITAL">TPMT</EMPH>) Genotype and Early Treatment Response to Mercaptopurine in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2005, 293, 1485. | 7.4 | 248 |
| 20 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and Tamoxifen Therapy. Clinical Pharmacology and Therapeutics, 2018, 103, 770-777. | 4.7 | 244 |
| 21 | Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 2003, 38, 978-988. | 7.3 | 244 |
| 22 | Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics and Genomics, 2002, 12, 429-436. | 5.7 | 236 |
| 23 | Association of the P-Glycoprotein Transporter MDR1 C3435T Polymorphism with the Susceptibility to Renal Epithelial Tumors. Journal of the American Society of Nephrology: JASN, 2002, 13, 1847-1854. | 6.1 | 233 |
| 24 | Therapeutic Efficacy of Intranasally Delivered Mesenchymal Stem Cells in a Rat Model of Parkinson Disease. Rejuvenation Research, 2011, 14, 3-16. | 1.8 | 225 |
| 25 | ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2005, 16, 1501-1511. | 6.1 | 208 |
| 26 | Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. Clinical Pharmacokinetics, 2015, 54, 709-735. | 3.5 | 207 |
| 27 | Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Medicine, 2013, 5, 1. | 8.2 | 198 |
| 28 | First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. Journal of Hepatology, 2016, 65, 483-489. | 3.7 | 187 |
| 29 | Clinical Aspects of the MDR1 (ABCB1) Gene Polymorphism. Therapeutic Drug Monitoring, 2004, 26, 180-185. | 2.0 | 170 |
| 30 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C19</i> and Proton Pump Inhibitor Dosing. Clinical Pharmacology and Therapeutics, 2021, 109, 1417-1423. | 4.7 | 157 |
| 31 | Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends in Pharmacological Sciences, 2013, 34, 126-135. | 8.7 | 150 |
| 32 | Thiopurine Treatment in Inflammatory Bowel Disease. Clinical Pharmacokinetics, 2007, 46, 187-208. | 3.5 | 145 |
| 33 | Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs). PLoS ONE, 2011, 6, e22163. | 2.5 | 140 |
| 34 | CYP2C19 Polymorphism and Proton Pump Inhibitors. Basic and Clinical Pharmacology and Toxicology, 2004, 95, 2-8. | 2.5 | 138 |
| 35 | PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo. Clinical Pharmacology and Therapeutics, 2012, 91, 1044-1052. | 4.7 | 131 |
| 36 | Omics and Drug Response. Annual Review of Pharmacology and Toxicology, 2013, 53, 475-502. | 9.4 | 130 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. <i>Lancet Infectious Diseases</i> , 2009, 9, 760-774. | 9.1 | 127 |
| 38 | Genetic Variants of Wnt Transcription Factor TCF-4 (TCF7L2) Putative Promoter Region Are Associated with Small Intestinal Crohn's Disease. <i>PLoS ONE</i> , 2009, 4, e4496. | 2.5 | 125 |
| 39 | DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. <i>Genome Medicine</i> , 2011, 3, 82. | 8.2 | 124 |
| 40 | Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 267-279. | 13.7 | 121 |
| 41 | Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 545-568. | 3.3 | 114 |
| 42 | Intranasal Delivery of Bone Marrow-Derived Mesenchymal Stem Cells, Macrophages, and Microglia to the Brain in Mouse Models of Alzheimer's and Parkinson's Disease. <i>Cell Transplantation</i> , 2014, 23, 123-139. | 2.5 | 114 |
| 43 | In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. <i>Nature Biotechnology</i> , 2015, 33, 584-586. | 17.5 | 113 |
| 44 | Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease. <i>Clinical Pharmacokinetics</i> , 2001, 40, 723-751. | 3.5 | 111 |
| 45 | The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779. | 9.4 | 110 |
| 46 | Organic Anion Transporters and Their Implications in Pharmacotherapy. <i>Pharmacological Reviews</i> , 2012, 64, 421-449. | 16.0 | 105 |
| 47 | Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). <i>Pharmacogenetics and Genomics</i> , 2004, 14, 309-318. | 5.7 | 104 |
| 48 | Nomenclature for alleles of the thiopurine methyltransferase gene. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 242-248. | 1.5 | 104 |
| 49 | Highly Multiplexed Genotyping of Thiopurine S-Methyltransferase Variants Using MALDI-TOF Mass Spectrometry: Reliable Genotyping in Different Ethnic Groups. <i>Clinical Chemistry</i> , 2008, 54, 1637-1647. | 3.2 | 103 |
| 50 | A phosphotyrosine switch regulates organic cation transporters. <i>Nature Communications</i> , 2016, 7, 10880. | 12.8 | 100 |
| 51 | Activating Mutation of the Renal Epithelial Chloride Channel ClC-Kb Predisposing to Hypertension. <i>Hypertension</i> , 2004, 43, 1175-1181. | 2.7 | 97 |
| 52 | A common variant mapping to CACNA1A is associated with susceptibility to exfoliation syndrome. <i>Nature Genetics</i> , 2015, 47, 387-392. | 21.4 | 97 |
| 53 | CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 201-209. | 4.7 | 93 |
| 54 | DNA Methylation of the <i>SLC16A3</i> Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome. <i>Clinical Cancer Research</i> , 2013, 19, 5170-5181. | 7.0 | 90 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy. <i>Clinical and Translational Science</i> , 2018, 11, 352-364. | 3.1 | 90 |
| 56 | Direct Transcriptional Regulation of Human Hepatic Cytochrome P450 3A4 (CYP3A4) by Peroxisome Proliferator-Activated Receptor Alpha (PPAR α). <i>Molecular Pharmacology</i> , 2013, 83, 709-718. | 2.3 | 88 |
| 57 | Mechanisms and assessment of statin-related muscular adverse effects. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 454-466. | 2.4 | 88 |
| 58 | Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. <i>Archives of Toxicology</i> , 2015, 89, 2089-2103. | 4.2 | 86 |
| 59 | High-Throughput Genotyping of Thiopurine S-Methyltransferase by Denaturing HPLC. <i>Clinical Chemistry</i> , 2001, 47, 548-555. | 3.2 | 84 |
| 60 | Developmental Pharmacokinetics. <i>Handbook of Experimental Pharmacology</i> , 2011, 205, 51-75. | 1.8 | 83 |
| 61 | Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. <i>Hepatology</i> , 2018, 67, 1609-1619. | 7.3 | 83 |
| 62 | 6-Thioguanosine Diphosphate and Triphosphate Levels in Red Blood Cells and Response to Azathioprine Therapy in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1007-1014. | 4.4 | 81 |
| 63 | Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver. <i>Frontiers in Pharmacology</i> , 2010, 1, 129. | 3.5 | 81 |
| 64 | Identification of Budesonide and Prednisone as Substrates of the Intestinal Drug Efflux Pump P-glycoprotein. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 578-583. | 1.9 | 78 |
| 65 | Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: Consequences for enzyme expression and busulfan conjugation*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 479-487. | 4.7 | 73 |
| 66 | Development of the "Passport: A Panel of Actionable Germline Genetic Variants for Preemptive Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 866-873. | 4.7 | 73 |
| 67 | Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 904-932. | 8.7 | 72 |
| 68 | Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. <i>Genetics in Medicine</i> , 2019, 21, 2145-2150. | 2.4 | 72 |
| 69 | Inflammation-Associated MicroRNA-130b Down-Regulates Cytochrome P450 Activities and Directly Targets CYP2C9. <i>Drug Metabolism and Disposition</i> , 2015, 43, 884-888. | 3.3 | 69 |
| 70 | Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPAR α in primary human hepatocytes. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 1218-1227. | 1.9 | 67 |
| 71 | Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 567. | 2.4 | 62 |
| 72 | Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. <i>Drug Metabolism Reviews</i> , 2011, 43, 499-523. | 3.6 | 59 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. <i>Gastroenterology</i> , 2001, 121, 500-501. | 1.3 | 56 |
| 74 | Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) â€“ association with decreased enzyme function. <i>Human Mutation</i> , 2006, 27, 976-976. | 2.5 | 55 |
| 75 | Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. <i>European Urology</i> , 2015, 68, 1016-1020. | 1.9 | 55 |
| 76 | Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1). <i>Clinical Cancer Research</i> , 2014, 20, 985-994. | 7.0 | 54 |
| 77 | Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. <i>Archives of Toxicology</i> , 2016, 90, 1555-1584. | 4.2 | 54 |
| 78 | Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologicallyâ€Based Pharmacokinetic Modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 322-331. | 2.5 | 54 |
| 79 | Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2746-2755. | 4.1 | 53 |
| 80 | Simultaneous Quantification of Eleven Thiopurine Nucleotides by Liquid Chromatography-Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2012, 84, 1294-1301. | 6.5 | 52 |
| 81 | Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. <i>Clinical Pharmacokinetics</i> , 2016, 55, 507-524. | 3.5 | 52 |
| 82 | Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen. <i>Frontiers in Pharmacology</i> , 2017, 8, 582. | 3.5 | 52 |
| 83 | Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease. <i>Cells</i> , 2019, 8, 595. | 4.1 | 50 |
| 84 | Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis. , 1998, 31, 159-165. | | 48 |
| 85 | GSTP1 and MDR1 Genotypes and Central Nervous System Relapse in Childhood Acute Lymphoblastic Leukemia. <i>International Journal of Hematology</i> , 2005, 81, 39-44. | 1.6 | 47 |
| 86 | Pharmacogene Variation Consortium Gene Introduction: <i>NUDT15</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1091-1094. | 4.7 | 45 |
| 87 | Population pharmacokinetics of oral busulfan in children. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 209-216. | 2.3 | 43 |
| 88 | Role of ABC Transporters in Fluoropyrimidine-Based Chemotherapy Response. <i>Advances in Cancer Research</i> , 2015, 125, 217-243. | 5.0 | 43 |
| 89 | Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. <i>Blood</i> , 2018, 131, 2466-2474. | 1.4 | 43 |
| 90 | Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 57-61. | 4.7 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Monitoring of Thiopurine Methyltransferase Activity in Postsurgical Patients With Crohn's Disease During 1 Year of Treatment With Azathioprine or Mesalazine. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 1-5. | 2.0 | 41 |
| 92 | Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis. <i>Frontiers in Pharmacology</i> , 2011, 2, 41. | 3.5 | 41 |
| 93 | TCF-1-mediated Wnt signaling regulates Paneth cell innate immune defense effectors HD-5 and -6: implications for Crohn's disease. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G487-G498. | 3.4 | 41 |
| 94 | Comprehensive Metabolomic and Lipidomic Profiling of Human Kidney Tissue: A Platform Comparison. <i>Journal of Proteome Research</i> , 2017, 16, 933-944. | 3.7 | 41 |
| 95 | Solute carrier transporter and drug-related nephrotoxicity: the impact of proximal tubule cell models for preclinical research. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 395-408. | 3.3 | 40 |
| 96 | Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 3181-3193. | 5.1 | 40 |
| 97 | Differential Effects of Targeted Disruption of Thiopurine Methyltransferase on Mercaptopurine and Thioguanine Pharmacodynamics. <i>Cancer Research</i> , 2007, 67, 4965-4972. | 0.9 | 39 |
| 98 | Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST). <i>BMC Cancer</i> , 2015, 15, 57. | 2.6 | 39 |
| 99 | Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma. <i>Drug Metabolism and Disposition</i> , 2014, 42, 2033-2040. | 3.3 | 38 |
| 100 | CYP3A5 Genotype is Associated with Diagnosis of Hypertension in Elderly Patients. <i>Molecular Diagnosis and Therapy</i> , 2005, 5, 191-195. | 3.3 | 36 |
| 101 | Data collection as a barrier to personalized medicine. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 68-71. | 8.7 | 36 |
| 102 | Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na ⁺ -taurocholate cotransporting polypeptide inhibitor. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 6815-6825. | 3.7 | 35 |
| 103 | Neuroprotective, Neurogenic, and Amyloid Beta Reducing Effect of a Novel Alpha 2-Adrenoblocker, Mesedin, on Astroglia and Neuronal Progenitors upon Hypoxia and Glutamate Exposure. <i>International Journal of Molecular Sciences</i> , 2018, 19, 9. | 4.1 | 35 |
| 104 | Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin. <i>European Urology Focus</i> , 2019, 5, 608-618. | 3.1 | 35 |
| 105 | Maternal nutrient restriction during pregnancy and lactation leads to impaired right ventricular function in young adult baboons. <i>Journal of Physiology</i> , 2017, 595, 4245-4260. | 2.9 | 34 |
| 106 | From genomic medicine to precision medicine: highlights of 2015. <i>Genome Medicine</i> , 2016, 8, 12. | 8.2 | 32 |
| 107 | Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. <i>Genome Medicine</i> , 2020, 12, 32. | 8.2 | 32 |
| 108 | Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, . | 6.0 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPAR α -tr, autonomously regulates proliferative and pro-inflammatory genes. <i>BMC Cancer</i> , 2015, 15, 488. | 2.6 | 31 |
| 110 | Age-Dependent Astroglial Vulnerability to Hypoxia and Glutamate: The Role for Erythropoietin. <i>PLoS ONE</i> , 2013, 8, e77182. | 2.5 | 30 |
| 111 | Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. <i>Pharmaceutics</i> , 2020, 12, 578. | 4.5 | 30 |
| 112 | Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 370, 124-30. | 3.0 | 29 |
| 113 | Peroxisome proliferator-activated receptor alpha, PPAR α , directly regulates transcription of cytochrome P450 CYP2C8. <i>Frontiers in Pharmacology</i> , 2015, 6, 261. | 3.5 | 29 |
| 114 | Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. <i>Scientific Reports</i> , 2016, 6, 29930. | 3.3 | 29 |
| 115 | PDK1 Determines Collagen-Dependent Platelet Ca ²⁺ Signaling and Is Critical to Development of Ischemic Stroke In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1507-1516. | 2.4 | 29 |
| 116 | Selective p38 α MAP kinase/MAPK14 inhibition in enzymatically modified LDL α -stimulated human monocytes: implications for atherosclerosis. <i>FASEB Journal</i> , 2017, 31, 674-686. | 0.5 | 29 |
| 117 | Using Trade Names. <i>Archives of Internal Medicine</i> , 2002, 162, 1065. | 3.8 | 27 |
| 118 | Pharmacogenomics: a key component of personalized therapy. <i>Genome Medicine</i> , 2012, 4, 93. | 8.2 | 27 |
| 119 | Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 296-307. | 2.5 | 27 |
| 120 | Genetic Biomarkers in Epilepsy. <i>Neurotherapeutics</i> , 2014, 11, 324-333. | 4.4 | 26 |
| 121 | Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 131-144. | 1.5 | 26 |
| 122 | Cell motility and migration as determinants of stem cell efficacy. <i>EBioMedicine</i> , 2020, 60, 102989. | 6.1 | 26 |
| 123 | Comparison of Different Risk Classification Systems in 558 Patients with Gastrointestinal Stromal Tumors after R0-Resection. <i>Frontiers in Pharmacology</i> , 2016, 7, 504. | 3.5 | 25 |
| 124 | Thiopurine S-methyltransferase as a target for drug interactions. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 395-398. | 1.9 | 24 |
| 125 | Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). <i>American Heart Journal</i> , 2018, 198, 152-159. | 2.7 | 24 |
| 126 | MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2015, 6, 30615-30627. | 1.8 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 227-237. | 4.7 | 23 |
| 128 | Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 201-211. | 4.7 | 23 |
| 129 | Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 349-365. | 3.1 | 22 |
| 130 | <i>ABCC11</i> /MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. <i>Pharmacogenomics</i> , 2013, 14, 1433-1448. | 1.3 | 21 |
| 131 | Simultaneous quantification of mefloquine (+)- and (âˆ™)-enantiomers and the carboxy metabolite in dried blood spots by liquid chromatography/tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 968, 32-39. | 2.3 | 21 |
| 132 | Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. <i>Pharmacogenomics</i> , 2020, 21, 325-335. | 1.3 | 21 |
| 133 | Determination of 6-Thioguanosine Diphosphate and Triphosphate and Nucleoside Diphosphate Kinase Activity in Erythrocytes: Novel Targets for Thiopurine Therapy?. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 119-128. | 2.0 | 20 |
| 134 | The earwax-associated SNP c.538G>A (G180R) in <i>ABCC11</i> is not associated with breast cancer risk in Europeans. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 993-999. | 2.5 | 20 |
| 135 | Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients. <i>International Journal of Cancer</i> , 2020, 146, 2475-2487. | 5.1 | 20 |
| 136 | Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, . | 4.0 | 20 |
| 137 | A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1398-1407. | 4.7 | 19 |
| 138 | SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells. <i>Cell Reports</i> , 2020, 32, 108184. | 6.4 | 19 |
| 139 | Association of <i>CYP2C19</i> and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1142-1152. | 2.4 | 18 |
| 140 | Variability and Heritability of Thiamine Pharmacokinetics With Focus on OCT1 Effects on Membrane Transport and Pharmacokinetics in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 628-638. | 4.7 | 18 |
| 141 | Metabolic Drug Response Phenotyping in Colorectal Cancer Organoids by LC-QTOF-MS. <i>Metabolites</i> , 2020, 10, 494. | 2.9 | 18 |
| 142 | Mucosal Improvement in Patients With Moderate to Severe Postoperative Endoscopic Recurrence of Crohn's Disease and Azathioprine Metabolite Levels. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 590-598. | 1.9 | 17 |
| 143 | Sex-dimorphic acceleration of pericardial, subcutaneous, and plasma lipid increase in offspring of poorly nourished baboons. <i>International Journal of Obesity</i> , 2018, 42, 1092-1096. | 3.4 | 17 |
| 144 | Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 661-670. | 4.7 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Functional characterization of protein variants of the human multidrug transporter ABCB2 by a novel targeted expression system in fibrosarcoma cells. <i>Human Mutation</i> , 2012, 33, 750-762. | 2.5 | 16 |
| 146 | Tamoxifen Pharmacogenetics and Metabolism: The Same Is Not the Same. <i>Journal of Clinical Oncology</i> , 2019, 37, 1981-1982. | 1.6 | 16 |
| 147 | Physiologically based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 494-511. | 2.5 | 16 |
| 148 | Optimized protocol for metabolomic and lipidomic profiling in formalin-fixed paraffin-embedded kidney tissue by LC-MS. <i>Analytica Chimica Acta</i> , 2020, 1134, 125-135. | 5.4 | 15 |
| 149 | Translational learning from clinical studies predicts drug pharmacokinetics across patient populations. <i>Npj Systems Biology and Applications</i> , 2017, 3, 11. | 3.0 | 14 |
| 150 | Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters. <i>Pharmaceutics</i> , 2021, 13, 369. | 4.5 | 14 |
| 151 | Transport studies with 5-aminosalicylate. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 871-875. | 1.9 | 13 |
| 152 | Achieving the World Health Organization's vision for clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 223-227. | 2.4 | 13 |
| 153 | Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling. <i>Journal of Proteome Research</i> , 2018, 17, 3039-3049. | 3.7 | 13 |
| 154 | Hypertonicity-Affected Genes Are Differentially Expressed in Clear Cell Renal Cell Carcinoma and Correlate with Cancer-Specific Survival. <i>Cancers</i> , 2020, 12, 6. | 3.7 | 13 |
| 155 | Data driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 782-793. | 2.5 | 13 |
| 156 | External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease. <i>Pharmaceutics</i> , 2021, 13, 1368. | 4.5 | 13 |
| 157 | Mechanisms of Clinical Resistance to Small Molecule Tyrosine Kinase Inhibitors Targeting Oncogenic Tyrosine Kinases. <i>Molecular Diagnosis and Therapy</i> , 2005, 5, 101-112. | 3.3 | 12 |
| 158 | Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. <i>Scientific Reports</i> , 2020, 10, 12457. | 3.3 | 12 |
| 159 | Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy. <i>Review of Diabetic Studies</i> , 2015, 12, 363-376. | 1.3 | 12 |
| 160 | Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. <i>Epilepsy Research</i> , 2017, 135, 64-70. | 1.6 | 11 |
| 161 | Open letter on access to the BIA 10-2474 clinical trial data. <i>Lancet, The</i> , 2017, 389, 156. | 13.7 | 11 |
| 162 | Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. <i>BMC Medicine</i> , 2018, 16, 108. | 5.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Ten years of Genome Medicine. <i>Genome Medicine</i> , 2019, 11, 7. | 8.2 | 11 |
| 164 | Organic cation transporter pharmacogenomics and drug-drug interaction. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 707-711. | 3.1 | 10 |
| 165 | Enzymatically Modified Low-Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease. <i>Journal of the American Heart Association</i> , 2015, 4, e002156. | 3.7 | 10 |
| 166 | Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. <i>Genome Medicine</i> , 2016, 8, 119. | 8.2 | 10 |
| 167 | The fruit fly <i>Drosophila melanogaster</i> as an innovative preclinical ADME model for solute carrier membrane transporters, with consequences for pharmacology and drug therapy. <i>Drug Discovery Today</i> , 2018, 23, 1746-1760. | 6.4 | 10 |
| 168 | Modulating endothelial adhesion and migration impacts stem cell therapies efficacy. <i>EBioMedicine</i> , 2020, 60, 102987. | 6.1 | 10 |
| 169 | β -2-Adrenergic Receptor in Liver Fibrosis: Implications for the Adrenoblocker Mesedin. <i>Cells</i> , 2020, 9, 456. | 4.1 | 10 |
| 170 | Two experts and a newbie: [¹⁸ F]PARPi vs [¹⁸ F]FTT vs [¹⁸ F]FPyPARP—a comparison of PARP imaging agents. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 834-846. | 6.4 | 10 |
| 171 | The importance of drug transporter characterization to precision medicine. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 361-365. | 3.3 | 9 |
| 172 | Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs. <i>Epilepsy Research</i> , 2018, 141, 83-89. | 1.6 | 9 |
| 173 | Clinically Relevant OATP2B1 Inhibitors in Marketed Drug Space. <i>Molecular Pharmaceutics</i> , 2020, 17, 488-498. | 4.6 | 9 |
| 174 | The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1906-1913. | 3.3 | 8 |
| 175 | Interplay between Endothelin and Erythropoietin in Astroglia: The Role in Protection against Hypoxia. <i>International Journal of Molecular Sciences</i> , 2014, 15, 2858-2875. | 4.1 | 8 |
| 176 | Ligand-dependent and -independent regulation of human hepatic sphingomyelin phosphodiesterase acid-like 3A expression by pregnane X receptor and crosstalk with liver X receptor. <i>Biochemical Pharmacology</i> , 2017, 136, 122-135. | 4.4 | 8 |
| 177 | Prevalence of a First-Degree Relative With Colorectal Cancer and Uptake of Screening Among Persons 40 to 54 Years Old. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2535-2543.e3. | 4.4 | 8 |
| 178 | Repurposing Riociguat for Treatment of Refractory Angina Resulting From Coronary Spasm. <i>JACC: Case Reports</i> , 2021, 3, 392-396. | 0.6 | 8 |
| 179 | Genetic and Epigenetic Regulation of Organic Cation Transporters. <i>Handbook of Experimental Pharmacology</i> , 2021, 266, 81-100. | 1.8 | 8 |
| 180 | 2012 highlights in translational 'omics. <i>Genome Medicine</i> , 2013, 5, 10. | 8.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 181 | A Web-based survey among adults aged 40â€“54Âyears was time effective and yielded stable response patterns. <i>Journal of Clinical Epidemiology</i> , 2019, 105, 10-18. | 5.0 | 7 |
| 182 | The cytosolic isoform of glutaredoxin 2 promotes cell migration and invasion. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129599. | 2.4 | 7 |
| 183 | Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins. <i>British Journal of Pharmacology</i> , 2021, 178, 1459-1474. | 5.4 | 7 |
| 184 | Stereoselective quantification of phase 1 and 2 metabolites of clomiphene in human plasma and urine. <i>Talanta</i> , 2021, 221, 121658. | 5.5 | 6 |
| 185 | Nelfinavir and Its Active Metabolite M8 Are Partial Agonists and Competitive Antagonists of the Human Pregnane X Receptor. <i>Molecular Pharmacology</i> , 2021, 99, 184-196. | 2.3 | 6 |
| 186 | Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model. <i>Cancers</i> , 2022, 14, 1158. | 3.7 | 6 |
| 187 | Hepatic Expression of the Na ⁺ -Taurocholate Cotransporting Polypeptide Is Independent from Genetic Variation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7468. | 4.1 | 6 |
| 188 | Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC. <i>World Journal of Urology</i> , 2022, 40, 739-746. | 2.2 | 5 |
| 189 | Molybdenum Cofactor Catabolism Unravels the Physiological Role of the Drug Metabolizing Enzyme Thiopurine Sâ€Methyltransferase. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 808-816. | 4.7 | 5 |
| 190 | CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL. <i>Leukemia</i> , 2022, 36, 2050-2063. | 7.2 | 5 |
| 191 | Comment on â€œEpigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatinâ€• <i>Science Translational Medicine</i> , 2017, 9, . | 12.4 | 4 |
| 192 | Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. <i>Pharmaceuticals</i> , 2021, 14, 115. | 3.8 | 4 |
| 193 | p110Î³/Î´ Double-Deficiency Induces Eosinophilia and IgE Production but Protects from OVA-Induced Airway Inflammation. <i>PLoS ONE</i> , 2016, 11, e0159310. | 2.5 | 3 |
| 194 | Pharmacokinetics and pharmacodynamics of thiopurines in an inÂvitro model of human hepatocytes: Insights from an innovative mass spectrometry assay. <i>Chemico-Biological Interactions</i> , 2017, 275, 189-195. | 4.0 | 3 |
| 195 | Validation of a high-performance liquid chromatography method for thiopurine S-methyltransferase activity in whole blood using 6-mercaptopurine as substrate. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 803-809. | 2.3 | 3 |
| 196 | Identification and characterization of novel splice variants of human farnesoid X receptor. <i>Archives of Biochemistry and Biophysics</i> , 2021, 705, 108893. | 3.0 | 3 |
| 197 | ADME Pharmacogenetics and Its Impact on Drugâ€“Drug Interactions. , 2010, , 51-74. | | 3 |
| 198 | How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper. <i>British Journal of Clinical Pharmacology</i> , 2022, , . | 2.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | (Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 511. | 2.5 | 3 |
| 200 | Richtlinie: Labormedizinische Diagnostik bei der Therapie mit TPMT (Thiopurin-S-Methyltransferase)-abhängigen Pharmaka. Guidelines for the laboratory management of thiopurine drug therapy. <i>Das Medizinische Laboratorium</i> , 2004, 28, 477-482. | 0.0 | 2 |
| 201 | CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth. <i>Biochemical Pharmacology</i> , 2020, 172, 113770. | 4.4 | 2 |
| 202 | Development and Experimental Validation of Regularized Machine Learning Models Detecting New, Structurally Distinct Activators of PXR. <i>Cells</i> , 2022, 11, 1253. | 4.1 | 2 |
| 203 | A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 2 |
| 204 | DETERMINANTS OF NON-RESPONSE IN HELICOBACTER PYLORI ERADICATION TRIALS. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1471-1471. | 2.8 | 1 |
| 205 | No association of genetic variants in TLR4, TNF- α , IL10, IFN- γ , and IL37 in cytomegalovirus-positive renal allograft recipients with active CMV infection – Subanalysis of the prospective randomised VIPP study. <i>PLoS ONE</i> , 2021, 16, e0246118. | 2.5 | 1 |
| 206 | Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. <i>Cancers</i> , 2021, 13, 2432. | 3.7 | 1 |
| 207 | A call to caution when hydroxychloroquine is given to elderly patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 106, 265-268. | 3.3 | 1 |
| 208 | Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the Thiopurine S-Methyltransferase Gene. , 2008, , 173-201. | | 1 |
| 209 | HETEROGENEITY OF DRUG RESPONSES AND INDIVIDUALIZATION OF THERAPY. , 2009, , 225-238. | | 1 |
| 210 | Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 6221. | 3.7 | 1 |
| 211 | The Authors??? Reply. <i>Clinical Pharmacokinetics</i> , 2007, 46, 805. | 3.5 | 0 |